Global Kidney Cancer Market Forecast to 2028 - Abbvie, Bayer Pharma, Merck & Co, GlaxoSmithKline, and Pfizer Are Dominating the Industry - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Kidney Cancer Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The global kidney cancer market is anticipated to grow at a substantial CAGR of 6.2% during the forecast period. As per the American Cancer Society, kidney cancer is among the 10 most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%). Reduced physical activity and excessive smoking and drinking are also a factor that is driving the kidney cancer market.

The global kidney cancer market is segmented based on the cancer type, cancer cell, diagnosis, and therapy. Based on the cancer type, the market is segmented into renal cell carcinoma (RCC), transitional cell cancer, Wilm's tumor (nephroblastoma), and others. Based on the cancer cell, the market is sub-segmented into a clear cell, papillary, and other. Based on the diagnosis, the market is sub-segmented into biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), and ultrasound. Based on therapy, the market is sub-segmented into surgery, immunotherapy, chemotherapy, radiation therapy, and cryotherapy.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market in the Asia-Pacific region is growing during the forecast period. The major countries contributing to the APAC region are China, Australia, Japan, and India. A large customer base, high consumption of Tabaco, and continuous increment in economy and healthcare facility are the major factor for the growth of the market in the region. The drugmaker launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer, in India. The drug is launched at an MRP that is approximately 96% lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg), and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).

The major companies serving the global kidney cancer market include Abbvie Inc., Bayer Pharma AG, Merck & Co., GlaxoSmithKline plc, and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib, for the treatment of renal cell carcinoma. Cabolong is available in 20mg, 40mg, and 60mg strengths at the pricing of below ?10,000 for a monthly treatment regimen with the highest strength.

The market is segmented by:

• Cancer Type
• Cancer Cell
• Diagnosis
• Therapy

The report covers:

• Comprehensive research methodology of the global pharmaceutical filtration market.
• A detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global pharmaceutical filtration market.
• Insights about market determinants that are stimulating the global pharmaceutical filtration market.
• Detailed and extensive market segments with the regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.

Companies Mentioned

• Abbvie Inc.
• Bayer Pharma AG
• GlaxoSmithKline plc
• Merck & Co.
• Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/oyp7xq